Rather than covering a random selection of immuno-oncology combinations, ICI Europe focuses on how checkpoint combinations can impact every stage of the cancer immunity cycle, enhancing the long-term success of immuno-oncology drug development.
Cutting through the noise and hype around the immuno-oncology field, this industry focused conference will use the cancer immunity cycle as a framework from which to investigate the most promising immuno-oncology approaches.
Don’t miss this opportunity to join Merck, Genentech, AstraZeneca, Bayer, Roche and many other leading organisations, to empower you to make the right decisions with your IO pipeline and lay the foundations for your future success.
“The talks were high quality and the interaction among participants was excellent.”
“Strong program, great speakers and a genuine focus on identifying solutions.”